Sino-Thai Cardiovascular Professional Corridor Successfully Held in Nanjing First Hospital

Nanjing, China, 07 April, 2021 - The Sino-Thai Cardiovascular Professional Corridor kicked off at Nanjing First Hospital on 19 March, 2021. The event, held as an online seminar, was attend by Professors from King Chulalongkorn Memorial Hospital in Thailand and Nanjing First Hospital at the invitation of Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”), a subsidiary of MicroPort Medical (Group) Co., Ltd. (00853.HK). An eclectic list of professors from a variety of hospitals spoke at the seminar, which marked a new milestone in Nanjing First Hospital’s active engagement with the Belt and Road initiative in the medical field.

During the two-hour seminar, experts from both sides shared knowledge and exchanged insights on PCI strategies for complex bifurcation lesions and TAVR treatment. Prof. Junjie Zhang, from Nanjing First Hospital, successfully demonstrated a live TAVR procedure for a patient with rheumatic aortic valve stenosis accompanied by severe adhesions. With collaboration among the cardiology, anesthesiology, and ultrasound departments, Prof. Zhang succeeded in implanting a VitaFlow® 27mm valve following a pre-dilation with an Alwide® 22mm balloon. The successful completion of this difficult procedure using a transcatheter aortic valve system demonstrated MicroPort®’s cutting-edge medical technology.

Prof. Wacin Buddhari of King Chulalongkorn Memorial Hospital said, “This seminar provided a valuable opportunity for doctors from both countries to re-educate ourselves and re-learn from each other. We had a fresh understanding of the DK-Crush technique, which will be of great help for future clinical practices.”

Founded in 1914, King Chulalongkorn Memorial Hospital is one of the largest hospitals in Thailand. Its cardiovascular center has become the largest for TAVR operations since its first procedure in 2014. The Department of Cardiology at Nanjing First Hospital has extensive experience in treating left main bifurcation lesions, pulmonary artery ablation, and structural heart disease interventions, boasting many of the world’s leading technologies in the field. The team is highly international and was recognized as a “Center of Excellence in Cardiology” by the European Society of Cardiology (ESC) in 2020.

About MicroPort Medical (Jiaxing) Co., Ltd

MicroPort Medical (Group) Co., Ltd. (00853.HK) has launched over 300 products available in over 10,000 hospitals around the world. One MicroPort® product is used every 6 seconds worldwide. Many patients in 140 countries along the Belt and Road have already benefited from MicroPort® products, and to date, MicroPort® has supplied approximately 61,900 cardiac stents to Thailand. The VitaFlow® Aortic Valve System, a representative product of the company, was launched in Thailand in November 2020, permitting Thai surgeons a high-quality and affordable method of treating patients with aortic valve disease. Additionally, MicroPort® EP’s products have also entered the local market. Most recently, the Daylily® embryo transfer catheter received registration approval in the country.